Organ‐on‐chip for advancing CAR therapy
Clinical & Translational Immunology · 2025-01 · 14 (2)
DOI: 10.1002/cti2.70024 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical & Translational Immunology, online erschienen am 26.02.2025. Verfasst von Lightson Ngashangva und 1 weiteren Autor:innen. Beteiligte Einrichtung: Biosensors and Biomicrofluidics Laboratory, Transdisciplinary Biology Program Rajiv Gandhi Centre for Biotechnology (RGCB) Thiruvananthapuram Kerala …. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Rajiv Gandhi Centre for Biotechnology, Department of Biotechnology, Ministry of Science and Technology, India.
Abstract (Originalsprache)
Despite great strides of progress, at least 60% of the responding patients relapse to CAR therapy across the blood malignancies. Off‐tumor toxicity apart from functional deficits, cytopenia and infection are the major unfavourable effect of CAR therapy. Models, which faithfully recapitulate the physiology and complexities of immunocompetent tumor microenvironment (TME), paused challenges in capturing potential off‐tumor effects of CAR therapy. Importantly, a landmark change in the legislation allows US Food and Drug Administration and New Drugs and Clinical Trial Rules in India encourages researchers to replace animal testing with cell culture approaches relevant to human system. Organ‐on‐chip (OOC) based on microfluidics technology can potentially emulate multiple biochemical and biophysical intricacies of blood and lymph flow at microscale. Nonetheless, how the evolving microfluidics technology can be enabling to real‐time testing of cell and gene is yet to be realised.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Biosensors and Biomicrofluidics Laboratory, Transdisciplinary Biology Program Rajiv Gandhi Centre for Biotechnology (RGCB) Thiruvananthapuram Kerala India.
- Synthetic Immunology Laboratory, Division of Cancer Research Rajiv Gandhi Centre for Biotechnology (RGCB) Thiruvananthapuram Kerala India.
Förderung
- Rajiv Gandhi Centre for Biotechnology, Department of Biotechnology, Ministry of Science and Technology, India
Zitieren
APA
Ngashangva, L., & Martin, S. (2025). Organ‐on‐chip for advancing CAR therapy. Clinical & Translational Immunology, 14(2). https://doi.org/10.1002/cti2.70024
Vancouver
Ngashangva L, Martin S. Organ‐on‐chip for advancing CAR therapy. Clinical & Translational Immunology. 2025;14(2). doi:10.1002/cti2.70024
BibTeX
@article{Ngashangva2025,
author = {Ngashangva, Lightson and Martin, Sunil},
title = {Organ‐on‐chip for advancing CAR therapy},
journal = {Clinical & Translational Immunology},
year = {2025},
volume = {14},
number = {2},
doi = {10.1002/cti2.70024}
}
EUVIMED